Thermo Fisher Scientific Return on Equity

Thermo Fisher Scientific (TMO.NE) currently reports a ROE of 12.93%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Thermo Fisher Scientific's ROE history and peer comparisons.

Thermo Fisher Scientific's ROE of 12.93% is higher than the Healthcare sector average of -100.59%. That is roughly 112.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Thermo Fisher Scientific's current 12.93% should be judged against Healthcare norms (sector average: -100.59%) and against TMO.NE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 12.93%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Thermo Fisher Scientific, and consider following TMO.NE for alerts when major investors trade the stock.

Thermo Fisher Scientific is classified in the Healthcare sector. On ROE, it currently shows 12.93% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TMO.NE with unrelated industries.